AARD (Aardvark Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


AARD Aardvark Therapeutics Inc AARD
12 GF Score
Price $4.79
! 1 Warning Sign
View Full Analysis

What is Aardvark Therapeutics EBITDA Margin %?

Aardvark Therapeutics AARD -5.34% 12 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates AARD with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Aardvark Therapeutics ranks worse than 106044.43% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aardvark Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-22.45 Mil. Aardvark Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Aardvark Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Aardvark Therapeutics  (NAS:AARD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aardvark Therapeutics EBITDA Margin % Related Terms

Aardvark Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Aardvark Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aardvark Therapeutics EBITDA Margin % Chart

Aardvark Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00

Aardvark Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AARD vs TELO, OKYO, SGMO: EBITDA Margin % Comparison

For the Biotechnology subindustry, Aardvark Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aardvark Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aardvark Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aardvark Therapeutics's EBITDA Margin % falls into.


AARD
12GF Score
Aardvark Therapeutics Inc AARD
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aardvark Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aardvark Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-62.689/0
= %

Aardvark Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-22.453/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Aardvark Therapeutics (AARD) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aardvark Therapeutics and its competitors. According to the industry distribution chart, Aardvark Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry.
Is Aardvark Therapeutics' EBITDA Margin % too high?
Aardvark Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Aardvark Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aardvark Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aardvark Therapeutics' EBITDA Margin % compare to TELO and OKYO?
According to the Biotechnology industry distribution chart, Aardvark Therapeutics ranks #999999 out of 943 companies for EBITDA Margin %. This places Aardvark Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aardvark Therapeutics and its competitors. Aardvark Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aardvark Therapeutics stock overvalued right now?
Aardvark Therapeutics (AARD) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Aardvark Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aardvark Therapeutics (AARD), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aardvark Therapeutics Business Description

Address 4370 La Jolla Village Drive, Suite 1050, San Diego, CA, USA, 92122
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
12GF Score

Get the complete analysis for AARD

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.79
Price